Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced on October 7, 2026, that it has commenced an offer to purchase outstanding warrants issued during its underwritten public offering on September 18, 2025. The company is offering $0.324 in cash per warrant, without interest, to holders who choose to tender their securities.
The offer aims to reduce the number of shares that could become outstanding upon the exercise of the warrants, thereby reducing potential dilution. Warrants that are successfully tendered will be retired and cancelled. Holders retain the option to exercise their warrants during the offer period or allow them to expire on March 18, 2030.
As of October 6, 2026, there were 12,345,707 warrants outstanding. The tender offer will remain open until one minute after 11:59 p.m., Eastern Time, on November 6, 2026. If all warrants are tendered, the company expects to pay out approximately $4.0 million, which will be funded from cash on hand. The offer is not conditioned on a minimum number of warrants being tendered and is subject to customary conditions.
